File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II trial of idarubicin in patients with advanced lymphoma

TitlePhase II trial of idarubicin in patients with advanced lymphoma
Authors
Issue Date1988
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1988, v. 21 n. 3, p. 261-264 How to Cite?
AbstractA phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m 2 i.v. or 15-70 mg/m 2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. The toxicities were myelosuppression, nausea and vomiting, and alopecia. Two patients with compromised cardiac function were observed to have further deterioration in the ejection fraction as measured by gated cardiac scan after idarubicin therapy. Further assessment of the activity of idarubicin against lymphoma is recommended in less heavily pretreated patients. The cardiac toxicity should be carefully monitored in future studies.
Persistent Identifierhttp://hdl.handle.net/10722/161763
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGillies, Hen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorRogers, Hen_US
dc.contributor.authorHarper, Pen_US
dc.contributor.authorParapia, Len_US
dc.contributor.authorCox, Gen_US
dc.contributor.authorJohnson, Sen_US
dc.date.accessioned2012-09-05T05:14:45Z-
dc.date.available2012-09-05T05:14:45Z-
dc.date.issued1988en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1988, v. 21 n. 3, p. 261-264en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161763-
dc.description.abstractA phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m 2 i.v. or 15-70 mg/m 2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. The toxicities were myelosuppression, nausea and vomiting, and alopecia. Two patients with compromised cardiac function were observed to have further deterioration in the ejection fraction as measured by gated cardiac scan after idarubicin therapy. Further assessment of the activity of idarubicin against lymphoma is recommended in less heavily pretreated patients. The cardiac toxicity should be carefully monitored in future studies.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAntibiotics, Antineoplastic - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBone Marrow Diseases - Chemically Induceden_US
dc.subject.meshDaunorubicin - Adverse Effects - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshDrug Evaluationen_US
dc.subject.meshHeart Diseases - Chemically Induceden_US
dc.subject.meshHumansen_US
dc.subject.meshIdarubicinen_US
dc.subject.meshLymphoma - Drug Therapyen_US
dc.titlePhase II trial of idarubicin in patients with advanced lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid3162850-
dc.identifier.scopuseid_2-s2.0-0023894452en_US
dc.identifier.volume21en_US
dc.identifier.issue3en_US
dc.identifier.spage261en_US
dc.identifier.epage264en_US
dc.identifier.isiWOS:A1988N055000017-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridGillies, H=6602582854en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridRogers, H=7202667688en_US
dc.identifier.scopusauthoridHarper, P=7201957807en_US
dc.identifier.scopusauthoridParapia, L=6603910400en_US
dc.identifier.scopusauthoridCox, G=7402494203en_US
dc.identifier.scopusauthoridJohnson, S=8789734900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats